With effective date January 1st 2013, SCOR has entered into a VIF (Value of In-Force) monetization transaction with BBVA Seguros, a Spanish leading insurance company, to reinsure a whole block of life risk insurance p
Le cancer colorectal est, avec le cancer du sein, du poumon et de la prostate, l’affection tumorale maligne la plus fréquente.
Lors de sa journée Investisseurs annuelle qui se tient aujourd’hui à Paris, SCOR présente de nouvelles informations et analyses démontrant que le Groupe atteint ses objectifs et est parfaitement positionné pour saisir
At its annual Investors’ Day being held today in Paris, SCOR presents updated information and analyses demonstrating that the Group is consistently delivering on its promises and is in a perfect position to seize new
At its annual Investors’ Day being held today in Paris, SCOR presents updated information and analyses demonstrating that the Group is consistently delivering on its promises and is in a perfect position to seize new
Life insurers have understood for a long time that certain differences among the population lead some groups to exhibit more favorable mortality than others.
Life insurers have understood for a long time that certain differences among the population lead some groups to exhibit more favorable mortality than others.
Résultats des neufs premiers mois de l'année 2012.
SCOR enregistre un résultat net de EUR 318 millions sur les neuf premiers mois de 2012, confirmant la solidité de son modèle économique
SCOR records net income of EUR 318 million for the first nine months of 2012, confirming the strength of its business model.
